Merck KGaA biosimilars news

Merck said it would invest EUR130 - EUR150 million ($168.2-$194.1 million) in biosimilars during 2015, depending on the outcome of ongoing Phase I studies. The investment comes on top of a EUR100 million ($129.4 million) commitment in 2014. The pharma also said it in-licensed an undisclosed late-stage biosimilar, which it plans to develop initially for smaller emerging markets.

Merck plans to start two to five Phase III trials of biosimilars for autoimmune disorders and cancer in 2015-16. The pharma said it plans to manufacture the biosimilars in Vevey, Switzerland. ...